Veru submits ind application to fda for the development of enobosarm to prevent muscle loss while augmenting fat loss in combination with glp-1 drugs for weight loss

Miami, fl, jan. 08, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced submission of an investigational new drug (ind) application with the u.s. food and drug administration for the development of enobosarm for obesity.
VERU Ratings Summary
VERU Quant Ranking